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Overall Outline
1. HIV & ART overview
◦ History, Epidemiology, transmission/risk, 
staging
◦ Med Class Overview, ART initiation
2. Treatment monitoring & Failure
◦ 2nd & 3rd line ART, toxicity/complications, 
monitoring
◦ Prevention
3. Opportunistic Infections & Hepatitis B
◦ OIs, ART considerations, Prophylaxis
◦ HBV dx, tx, surveillance, & HIV-HBV co-infection
4. Special Populations:
◦ Pregnancy, antenatal & intrapartum, infant care 
& pediatric
5. HIV/HBV Case-Based Application
1. Case Application
2. Wrap-up/review, miscellaneous items
5 session, 2 hours each
Source Materials
Liberia Integrated Guidelines for Prevention, Testing, Care, and Treatment of HIV and AIDS
◦ 5th edition, August 2019
WHO HIV Diagnosis, Treatment, and Opportunistic Infection Guidelines
◦ 2016, 2018 ART update
◦ https://www.who.int/publications/guidelines/hiv_aids/en/
WHO Hepatitis B treatment guidelines (2015)
◦ https://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/
ELWA Hepatitis B Treatment Protocol.
Zambia National Hepatitis B Treatment Protocol.
Reference Materials
Department of Health & Human Services. HIV Guidelines. USA. https://aidsinfo.nih.gov/guidelines
Fundamentals of HIV Medicine. American Academy of HIV Medicine. Oxford University Press. 2017 Edition. 
National HIV Curriculum. University of Washington & CDC. USA. https://www.hiv.uw.edu/
AIDS-defining conditions
Recurrent bacterial infections












































Variable & atypical sx!
Anemia, fever, weight loss
Management:
Don’t delay; if sick > empiric!
ART considerations:
CD4 <50 = ART within 2 weeks 
CD4 >50 = ART at 8 weeks
TB meningitis = generally defer ART until 8 weeks
Avoid: NVP, ATV/r, LPV/r, DRV/r
DTG: best option, but double dose of DTG for rifampicin
TB Preventive Therapy (TPT):
All HIV+, start w/ ART either:
• 6H (INH x6mo)
• 3HP (RFP/INH wkly x12)
Epidemiology:
PLHV: 10% annual & 50% 
lifetime risk
Most common cause of death
Diagnosis:
Think pre-test probability!
Xpert; smear (but most are negative); culture
If CD4 <200 -> routinely screen urine LAM
- if + => give TBT; does not r/o dz if neg
Mycobacterium
Reactivation OR primary disease
Cryptococcosis
Presentation:
Indolent, headache, AMS, +/-
fever, rash similar to molluscum
Diagnosis:
CrAg (serum (95% +) or CSF)
India Ink stain, ^opening pressure




Option 1: AmphoB/flucytosine x7d
Option 2: Fluconazole/flucytosine x14d




Fluconazole 200mg daily for life
ART considerations:
Start ART only 5 weeks after
antifungal tx initiation
Prevention:











CT with ring enhancing lesions
CSF studies (PCR specific, not sensitive)
IgG negative = excellent NPV
Management:
Cotrim 960mg:
4 tab BID x6wk, then
2 tab BID x3mo, then
1 tab BID lifelone
ART considerations:
Start ART within 2-3 weeks
Prevention:
If CD4 <100 give cotrim ppx
Epidemiology:
CD4 <100
Results from reactivation of 
previously latent dz
Parasite
Reactivation of latent infection
Pneumocystis Jiroveci (carinii) 
Pneumonia (PJP)
Presentation:
Subacute, nonproductive cough, 





CSF studies (PCR specific, not sensitive)
IgG negative = excellent NPV
Management:
Cotrim x21d
If hypoxic give prednisolone 
x21d (start with cotrim)
ART considerations:









Nonspecific/indolent – fever, fatigue, 
diarrhea, weight loss, abd pain, diffuse LAD
Diagnosis:
Presumptive clinical diagnosis
Blood Culture x2 (90% sensitive by 14d 
growth)
Management:














Retinitis – floaters, flashes, field deficits, failing 
vision, often unilateral
CNS (encephalitis), GI (diarrhea, weight loss, 
esophagitis)
Diagnosis: clinical
Retinal exam, endoscopy (mucosal 
ulcerations, biopsy), CSF PCR
Management:
IV ganciclovir or intraviteral
injxn
ART considerations:






Risk factors: MSM, high HIV RNA, 
prior OI
ds-DNA herpes virus
Reactivation of latent infection
Histoplasmosis
Presentation: many variations
Disseminated: fever, wt loss, cough
Encephalitis, GI, hepatomegaly
Diagnosis:
CXR: nodules, diffuse patchy opacities
Urine Ag
Management:





2* ppx stopped after 1yr when on 
ART with undetectable RNA & 
Histoplasma Ag not detected
Epidemiology:































ART (sx stop when CD4 >100)
















Large oocysts on modified acid-fast 
stool microscopy
Management:

















Wet prep if vaginal
Management:
Oral: nystatin topical x7-14d
Esophageal: fluconazole x14d















Acyclovir x7d within 72hrs of 
symptom start














Pruritis; papules & thin short “burrows”

















Purple/red/brown patch > plaque > 
nodule
Cutaneous, mucous membrane, 
visceral organ (GI, pulm, lymphatic)





KS Stage T0 (adults with only 
cutaneous KS) = ART x3mo
KS Stage T1 (any pediatric & 










Vascular tumor caused by 
human herpes virus-8 (HHV-8)
Lymphoma
Presentation:




Consider if failure to improve after TB 






























IRIS (Immune Reconstitution 
Inflammatory Syndrome)
Disease- or pathogen-specific inflammatory state that may occur after initiation of ART
◦ Paradoxical: worsening of previously diagnosed disease
◦ Unmasking: appearance of previously undiagnosed disease
Rules of thumb:
◦ Treat the IRIS-specific condition as indicated
◦ Continue ART
TB-IRIS
◦ Give steroids (4 weeks)
